See more : Luoyang Northglass Technology Co.,Ltd (002613.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Valneva SE (VALN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Valneva SE, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- INNOKAIZ INDIA LIMITED (INNOKAIZ.BO) Income Statement Analysis – Financial Results
- Public Joint Stock Company ALROSA (ALRS.ME) Income Statement Analysis – Financial Results
- LEG Immobilien SE (LEGIF) Income Statement Analysis – Financial Results
- Sanderson Design Group plc (SDG.L) Income Statement Analysis – Financial Results
- Silver Lake Resources Limited (SVLKF) Income Statement Analysis – Financial Results
Valneva SE (VALN)
About Valneva SE
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 153.71M | 361.30M | 348.09M | 110.32M | 126.20M | 113.04M | 105.29M | 94.06M | 78.36M | 36.92M | 30.45M | 3.43M | 10.26M | 8.40M | 3.10M | 3.42M | 866.00K | 2.33M | 3.01M |
| Cost of Revenue | 100.88M | 324.44M | 187.92M | 54.30M | 49.97M | 43.43M | 45.98M | 43.08M | 46.96M | 17.14M | 16.51M | 11.10M | 6.72M | 6.54M | 5.26M | 2.75M | 1.68M | 726.00K | 475.00K |
| Gross Profit | 52.84M | 36.86M | 160.17M | 56.02M | 76.23M | 69.60M | 59.31M | 50.99M | 31.40M | 19.78M | 13.94M | -7.66M | 3.54M | 1.86M | -2.16M | 673.00K | -817.00K | 1.60M | 2.54M |
| Gross Profit Ratio | 34.37% | 10.20% | 46.01% | 50.78% | 60.40% | 61.58% | 56.33% | 54.20% | 40.07% | 53.57% | 45.78% | -223.38% | 34.50% | 22.11% | -69.80% | 19.69% | -94.34% | 68.83% | 84.22% |
| Research & Development | 59.89M | 104.92M | 173.28M | 84.45M | 37.88M | 12.19M | 23.36M | 24.59M | 25.37M | 22.24M | 21.42M | 12.89M | 12.17M | 13.13M | 9.87M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 47.80M | 34.07M | 47.61M | 38.01M | 27.51M | 36.30M | 15.55M | 14.41M | 14.39M | 14.14M | 14.72M | 4.18M | 262.00K | 3.69M | 3.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 48.75M | 23.51M | 23.64M | 7.52M | 14.62M | 11.74M | 17.88M | 16.64M | 9.12M | 2.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 96.55M | 57.58M | 71.25M | 45.52M | 42.13M | 48.04M | 33.42M | 31.05M | 23.52M | 14.14M | 14.72M | 4.18M | 262.00K | 3.69M | 3.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -21.52M | -12.20M | -22.98M | -18.85M | -3.07M | 19.83M | 6.49M | 37.79M | 2.48M | 7.15M | -91.00K | -798.00K | 8.39M | -636.00K | 3.38M | 3.83M | 3.97M | 1.82M | 3.97M |
| Operating Expenses | 134.92M | 150.31M | 221.56M | 111.13M | 76.95M | 63.34M | 63.27M | 93.43M | 51.36M | 43.53M | 36.05M | 16.26M | 8.65M | 16.81M | 3.38M | 3.83M | 3.97M | 1.82M | 3.97M |
| Cost & Expenses | 235.80M | 474.75M | 409.48M | 165.43M | 126.92M | 106.77M | 109.25M | 136.51M | 98.32M | 60.68M | 52.56M | 16.26M | 15.37M | 16.81M | 8.64M | 6.57M | 5.65M | 2.55M | 4.44M |
| Interest Income | 1.21M | 260.00K | 249.00K | 119.00K | 199.00K | 178.00K | 72.00K | 290.00K | 3.10M | 225.00K | 191.00K | 435.00K | 757.00K | 389.00K | 312.00K | 972.00K | 550.00K | 91.00K | 34.00K |
| Interest Expense | 23.33M | 19.05M | 16.96M | 10.74M | 2.63M | 3.79M | 5.06M | 6.09M | 9.72M | 4.39M | 1.21M | 533.00K | 699.00K | 786.00K | 161.00K | 207.00K | 154.00K | 25.00K | 81.00K |
| Depreciation & Amortization | 17.58M | 21.04M | 14.28M | 9.80M | 8.53M | 6.83M | 11.14M | 11.27M | 11.44M | 12.36M | 9.06M | 4.78M | 3.32M | 2.62M | 1.59M | 1.31M | 1.22M | 328.00K | 1.52M |
| EBITDA | -57.72M | -99.39M | -46.87M | -46.11M | 9.71M | 12.85M | 3.64M | -31.47M | 9.76M | -9.19M | -13.36M | -7.69M | 795.00K | -6.08M | -4.70M | -1.82M | -3.02M | 605.00K | 998.00K |
| EBITDA Ratio | -37.55% | -31.32% | -13.46% | -41.08% | 8.01% | 12.74% | 6.98% | -0.97% | -1.58% | -30.38% | -42.13% | -220.69% | -10.04% | -69.04% | -127.58% | -53.31% | -348.50% | 23.06% | 30.89% |
| Operating Income | -82.09M | -113.44M | -61.39M | -55.11M | 1.50M | 6.26M | -3.95M | -42.57M | -19.93M | -23.82M | -20.86M | -12.83M | -4.45M | -8.42M | -6.30M | -3.15M | -4.79M | -221.00K | -1.43M |
| Operating Income Ratio | -53.40% | -31.40% | -17.64% | -49.95% | 1.19% | 5.54% | -3.76% | -45.26% | -25.44% | -64.50% | -68.50% | -374.03% | -43.37% | -100.26% | -203.33% | -92.28% | -552.54% | -9.49% | -47.49% |
| Total Other Income/Expenses | -16.54M | -31.37M | -8.59M | -10.18M | -59.00K | -2.91M | -8.61M | -6.26M | -13.64M | -2.12M | -2.77M | -56.00K | 1.43M | -397.00K | 3.58M | 765.00K | 396.00K | -25.00K | 34.00K |
| Income Before Tax | -98.63M | -144.82M | -69.98M | -65.30M | -870.00K | 3.35M | -12.56M | -48.83M | -20.39M | -25.94M | -23.63M | -12.89M | -4.39M | -9.45M | -6.14M | -2.39M | -4.39M | -246.00K | -1.40M |
| Income Before Tax Ratio | -64.16% | -40.08% | -20.10% | -59.19% | -0.69% | 2.96% | -11.93% | -51.91% | -26.03% | -70.25% | -77.60% | -375.66% | -42.80% | -112.57% | -198.45% | -69.89% | -506.81% | -10.56% | -46.36% |
| Income Tax Expense | 2.80M | -1.54M | 3.45M | -909.00K | 874.00K | 88.00K | -1.08M | 356.00K | 224.00K | 334.00K | 348.00K | 96.00K | 26.00K | -1.49M | 0.00 | 24.00K | -1.03M | -3.00K | -176.00K |
| Net Income | -101.43M | -143.28M | -73.43M | -64.39M | -1.74M | 3.26M | -11.48M | -49.18M | -20.62M | -26.27M | -24.11M | -14.84M | -4.42M | -7.96M | -6.14M | -2.39M | -3.36M | -243.00K | -1.22M |
| Net Income Ratio | -65.99% | -39.66% | -21.09% | -58.37% | -1.38% | 2.89% | -10.91% | -52.29% | -26.31% | -71.15% | -79.19% | -432.56% | -43.06% | -94.84% | -198.45% | -69.89% | -388.22% | -10.43% | -40.52% |
| EPS | -1.46 | -2.48 | -1.50 | -1.42 | -0.04 | 0.08 | -0.30 | -1.32 | -0.56 | -0.94 | -1.22 | -1.40 | -0.42 | -0.92 | -0.84 | -0.28 | -0.52 | -0.05 | -0.24 |
| EPS Diluted | -1.46 | -2.48 | -1.50 | -1.42 | -0.04 | 0.08 | -0.30 | -1.32 | -0.56 | -0.94 | -1.22 | -1.40 | -0.42 | -0.92 | -0.84 | -0.28 | -0.52 | -0.05 | -0.24 |
| Weighted Avg Shares Out | 69.31M | 57.74M | 48.81M | 45.38M | 45.87M | 40.26M | 38.27M | 37.33M | 36.37M | 27.75M | 19.67M | 10.63M | 10.50M | 8.75M | 7.31M | 8.42M | 6.53M | 5.10M | 5.10M |
| Weighted Avg Shares Out (Dil) | 69.31M | 57.74M | 48.81M | 45.38M | 45.87M | 40.80M | 38.72M | 37.33M | 36.37M | 27.75M | 19.67M | 10.63M | 10.54M | 8.75M | 7.31M | 8.42M | 6.53M | 5.10M | 5.10M |
Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
First-Half Sales Performance in Line with Full-Year 2024 Guidance Total revenues of €70.8 million, including product sales of €68.3 million, in line with anticipated supply and sales phasing Net Profit of €34.0 million, including proceeds from PRV sale Operating profit of...
Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
Saint-Herblain (France) and Schlieren (Zurich), August 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced that the...
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
What could be better than viable enterprises within the biotechnology industry? Try biotech stocks under $10.
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 149% upside potential for Valneva (VALN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya Vaccine
Oslo, Norway, and Saint-Herblain, France, July 22, 2024—The Coalition for Epidemic Preparedness Innovations (CEPI) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, have expanded their partnership to support broader access to the world's first chikungunya vaccine,...
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
New York, NY and Saint-Herblain (France), July 17, 2024 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the participants of the Phase 3 trial “Vaccine Against Lyme for Outdoor Recreationists” (VALOR) have...
Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine
Valneva (VALN) gets European Commission???s marketing authorization in Europe for Valneva?
Valneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ®
Saint Herblain (France), July 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva's single-dose vaccine, IXCHIQ®, for the prevention of...
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
Saint-Herblain (France), June 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting (CGM)...
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval
Valneva's (VALN) IXCHIQ, the world's only licensed chikungunya vaccine, is a critical tool in combating this public health threat.
Source: https://incomestatements.info
Category: Stock Reports